<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; consumer</title>
	<atom:link href="http://www.tapanray.in/tag/consumer/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Deliver Patient-Perceived Value &#8211; Not Incrementally But In Quantum Measure</title>
		<link>http://www.tapanray.in/deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure</link>
		<comments>http://www.tapanray.in/deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure/#comments</comments>
		<pubDate>Mon, 19 Dec 2022 08:22:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[deliver]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[long-term]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[operational]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perceived]]></category>
		<category><![CDATA[Quantum]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategizing]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10737</guid>
		<description><![CDATA[Many critical functional areas of most drug companies, such as, marketing, manufacturing, supply chain, medical affairs, human resource, R&#38;D, quality assurance, information technology &#8211; traditionally work in silos. It doesn’t mean, though, that there isn’t any interaction between them. Nevertheless, &#8230; <a href="http://www.tapanray.in/deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/deliver-patient-perceived-value-not-incrementally-but-in-quantum-measure/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma To Leverage The Art of Turning Challenges Into Opportunities, Now</title>
		<link>http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now</link>
		<comments>http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/#comments</comments>
		<pubDate>Mon, 20 Jul 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[health care]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[problems]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[respelling]]></category>
		<category><![CDATA[talent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[touchpoints]]></category>
		<category><![CDATA[turning]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10179</guid>
		<description><![CDATA[Since, the dawn of the year 2020, the human population living in different countries, across the world are facing ‘lockdowns in different forms. Although essential, it severely restricts normal daily essential and other important activities of all. A large number &#8230; <a href="http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-to-leverage-the-art-of-turning-challenges-into-opportunities-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Pharma Industry A Late Learner, Always?</title>
		<link>http://www.tapanray.in/is-pharma-industry-a-late-learner-always/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-pharma-industry-a-late-learner-always</link>
		<comments>http://www.tapanray.in/is-pharma-industry-a-late-learner-always/#comments</comments>
		<pubDate>Mon, 23 Dec 2019 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Consumerism]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[diagnosis]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[E-Patients]]></category>
		<category><![CDATA[empowerment]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[episodes]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[fast]]></category>
		<category><![CDATA[Ferguson]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[late]]></category>
		<category><![CDATA[learner]]></category>
		<category><![CDATA[learning]]></category>
		<category><![CDATA[legacy]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reinvent the wheel]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thomas]]></category>
		<category><![CDATA[touchpoints]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9826</guid>
		<description><![CDATA[Several upcoming concepts in the pharmaceutical industry are becoming buzzwords today. But, most of these were recommended by stalwarts several decades ago. Interestingly, the prevailing scenario is no different, even related to wide-scale adoption of a number of cutting-edge technologies, &#8230; <a href="http://www.tapanray.in/is-pharma-industry-a-late-learner-always/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-pharma-industry-a-late-learner-always/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Are Pharma Business Ethics And Performance Interlinked?</title>
		<link>http://www.tapanray.in/are-pharma-business-ethics-and-performance-interlinked/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=are-pharma-business-ethics-and-performance-interlinked</link>
		<comments>http://www.tapanray.in/are-pharma-business-ethics-and-performance-interlinked/#comments</comments>
		<pubDate>Mon, 11 Nov 2019 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[expect]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Interlinked]]></category>
		<category><![CDATA[multiplier]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[systemic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9768</guid>
		<description><![CDATA[Way back in the 1960s, many could realize that of upcoming consumer-focused business environment will bring business practices under intense stakeholder scrutiny. This prompted both the business schools, as well as the commercial organizations to bring the concept of ‘business &#8230; <a href="http://www.tapanray.in/are-pharma-business-ethics-and-performance-interlinked/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/are-pharma-business-ethics-and-performance-interlinked/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Providing Unique Patient Experience &#8211; A New Brand Differentiator</title>
		<link>http://www.tapanray.in/providing-unique-patient-experience-a-new-brand-differentiator/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=providing-unique-patient-experience-a-new-brand-differentiator</link>
		<comments>http://www.tapanray.in/providing-unique-patient-experience-a-new-brand-differentiator/#comments</comments>
		<pubDate>Sun, 04 Mar 2018 23:50:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AR]]></category>
		<category><![CDATA[Augmented]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[differentiator]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[Flatiron]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Internet of Things]]></category>
		<category><![CDATA[IoT]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[Virtual reality]]></category>
		<category><![CDATA[VR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8887</guid>
		<description><![CDATA[“Pharma industry, including the patients in India are so different from other countries. Thus, any strategic shift from conventional pharma brand marketing approach &#8211; going beyond doctors, won’t be necessary.” The above mindset is interesting and may well hold good &#8230; <a href="http://www.tapanray.in/providing-unique-patient-experience-a-new-brand-differentiator/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/providing-unique-patient-experience-a-new-brand-differentiator/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Relevant Is A Pharma Brand Name To Patients?</title>
		<link>http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-relevant-is-a-pharma-brand-name-to-patients</link>
		<comments>http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/#comments</comments>
		<pubDate>Mon, 26 Feb 2018 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[counter]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTC]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[relevant]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8832</guid>
		<description><![CDATA[Are brand names necessary for medicines? Well – its’s a contentious issue, at least, as on date. It becomes the subject of a raging debate when the same question is slightly modified to: &#8211; Are brand names necessary for prescription &#8230; <a href="http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Digiceuticals’: A Force Multiplier to Contain Chronic Diseases</title>
		<link>http://www.tapanray.in/digiceuticals-a-force-multiplier-to-contain-chronic-diseases/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=digiceuticals-a-force-multiplier-to-contain-chronic-diseases</link>
		<comments>http://www.tapanray.in/digiceuticals-a-force-multiplier-to-contain-chronic-diseases/#comments</comments>
		<pubDate>Sun, 22 Oct 2017 23:30:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[app]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[digiceuticals]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[disorders]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[smartphone]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[suppliers]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8373</guid>
		<description><![CDATA[There is a growing need for more effective prevention, treatment or management of many serious Noninfectious Chronic Diseases (NCDs), with greater safety and at a lesser cost. As a major step in this direction, ‘digiceuticals’ or ‘digital therapeutics’ are now &#8230; <a href="http://www.tapanray.in/digiceuticals-a-force-multiplier-to-contain-chronic-diseases/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/digiceuticals-a-force-multiplier-to-contain-chronic-diseases/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Expensive Is Drug Innovation?</title>
		<link>http://www.tapanray.in/how-expensive-is-drug-innovation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-expensive-is-drug-innovation</link>
		<comments>http://www.tapanray.in/how-expensive-is-drug-innovation/#comments</comments>
		<pubDate>Mon, 16 May 2016 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affairs]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[goods]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Internal]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[REAL]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tufts Centre]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7637</guid>
		<description><![CDATA[High prices for patented drugs are quite often attributed to the exorbitant cost of drug innovation, by the global pharma players. This argument is played, replayed again, again… and again by them, in various ways and forms, especially when many &#8230; <a href="http://www.tapanray.in/how-expensive-is-drug-innovation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-expensive-is-drug-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Drug Price Control The Key Growth Barrier For Indian Pharma Industry?</title>
		<link>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/#comments</comments>
		<pubDate>Mon, 19 Oct 2015 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AIOCD-AWACS]]></category>
		<category><![CDATA[apex]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[corollary]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Crocin Advance]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health care UHC]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[increases]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safeguard]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7183</guid>
		<description><![CDATA[The corollary of the above headline could well be: “Are drug price hikes the key growth driver for the Indian Pharmaceutical Market (IPM)?” Whenever the first question, as appears in the headline of this article: “Is drug price control a &#8230; <a href="http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
